Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vtv Theraptcs Cl A (VTVT)

Vtv Theraptcs Cl A (VTVT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vtv Theraptcs Cl A 3980 PREMIER DR SUITE 310 HIGH POINT NC 27265 USA

www.vtvtherapeutics.com Employees: 23 P: 336-841-0300 F: 336-841-0310

Sector:

Medical

Description:

vTv Therapeutics Inc. is a biopharmaceutical company which is engaged in the discovery and development of orally administered small molecule drug candidates to fill unmet medical needs. Its drug candidate for the treatment of Alzheimers disease includes azeliragon TTP488, which is in Phase III clinical trials; type II diabetes drug candidates include Glucokinase Activator TTP399 and GLP-1r Agonist TTP273 which completed Phase I clinical trials; products for the prevention of muscle weakness and treatment of inflammatory disorders include HPP593, HPP737 and HPP971 which is in Phase1 clinical trials. The Company's drug discovery platform consists of TTP Translational Technology. vTv Therapeutics Inc. is headquartered in High Point, North Carolina.

Key Statistics

Overview:

Market Capitalization, $K 136,383
Enterprise Value, $K 99,633
Shares Outstanding, K 3,938
Annual Sales, $ 1,020 K
Annual Net Income, $ -18,460 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -8,700 K
EBIT, $ -29,810 K
EBITDA, $ -29,720 K
60-Month Beta 0.50
% of Insider Shareholders 4.20%
% of Institutional Shareholders 17.51%
Float, K 3,773
% Float 95.80%
Short Volume Ratio 0.67

Growth:

1-Year Return 120.57%
3-Year Return 21.85%
5-Year Return -58.97%
5-Year Revenue Growth -63.04%
5-Year Earnings Growth 78.38%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.08 on 11/06/25
Next Earnings Date 03/19/26
Earnings Per Share ttm -3.32
EPS Growth vs. Prev Qtr -17.39%
EPS Growth vs. Prev Year -22.73%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 11/21/23

VTVT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -97.64%
Return-on-Assets % -47.84%
Profit Margin % -1,809.80%
Debt/Equity 0.00
Price/Sales 132.05
Price/Cash Flow N/A
Price/Book 1.90
Book Value/Share 17.90
Interest Coverage -0.66
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar